CN¥ 8.24
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Weak growth
Data is available to registered users only
Data is available to registered users only
About
Cabio Biotech (Wuhan) Co., Ltd. engages in the research, development, production and sale of polyunsaturated fatty acids and nutrition products. Its products include arachidonic acids (ARA), docosahexaenoic acids (DHA), natural beta-carotene products, infant formula food, functional healthcare food and dietary supplements. The company was founded on September 22, 2004 and is headquartered in Wuhan, China.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on E
Data is available to registered users only